Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2018

01-12-2018 | Clinical trial

Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy

Authors: Seung Hyuck Jeon, Kyung Hwan Shin, Jin Ho Kim, Kyubo Kim, In Ah Kim, Kyung-Hun Lee, Tae-Yong Kim, Seock-Ah Im

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Abstract

Purpose

In the present study, the ability of adjuvant trastuzumab to reduce locoregional recurrence in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer receiving adjuvant chemotherapy and radiotherapy (RT) was investigated.

Materials and methods

We retrospectively included 520 patients with HER2-overexpressing breast cancer who received surgery followed by adjuvant RT and cytotoxic chemotherapy from 2003 to 2011. Adjuvant trastuzumab was administered to 286 patients. Propensity score matching was conducted to compare trastuzumab-treated and non-treated cohorts.

Results

Median follow-up duration was 7.1 years (range 1.1–14.1 years). Propensity score matching yielded 171 matched pairs of patients with no significantly different clinical factors. An improved 7-year locoregional control (LRC) rate was observed in the trastuzumab-treated cohort compared with the non-treated cohort (95.6% vs. 89.9%, p = 0.014). Based on multivariate analysis, hormone receptor negativity (hazard ratio [HR] = 5.348, p = 0.007), positive lymph node ratio > 0.25 (HR = 2.549, p = 0.040), and lack of adjuvant trastuzumab (HR = 3.401, p = 0.017) were identified as significant risk factors for poor LRC. Adjuvant trastuzumab significantly reduced the locoregional recurrence rate in patients with one or two risk factors (7-year LRC = 95.0% vs. 84.2%, p = 0.007); however, the benefit of adjuvant trastuzumab was non-significant in patients with no risk factors (7-year LRC = 95.8% vs. 97.9%, p = 0.75).

Conclusions

Adjuvant trastuzumab improved LRC in patients with HER2-overexpressing breast cancer receiving adjuvant RT and cytotoxic chemotherapy, especially in hormone receptor-negative, HER2-enriched subtype, and high positive lymph node ratio breast cancer.
Literature
1.
Ross JS, Fletcher JA (1999) The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 9:125–138CrossRef
2.
Koo T, Kim IA (2016) Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment. Radiat Oncol J 34:1–9CrossRef
3.
Horton JK, Jagsi R, Woodward WA et al (2018) Breast cancer biology: clinical implications for breast radiation therapy. Int J Radiat Oncol Biol Phys 100:23–37CrossRef
4.
Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205CrossRef
5.
Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744–3752CrossRef
6.
Mavroudis D, Saloustros E, Malamos N et al (2015) Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 26:1333–1340PubMed
7.
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127–2135CrossRef
8.
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), Darby S, McGale P et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707–1716CrossRef
9.
Wollman R, Yahalom J, Maxy R et al (1994) Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys 30:991–998CrossRef
10.
Pietras RJ, Poen JC, Gallardo D et al (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347–1355PubMed
11.
Liang K, Lu Y, Ang KK et al (2003) Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2:1113–1120PubMed
12.
Kiess AP, McArthur HL, Mahoney K et al (2012) Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer 118:1982–1988CrossRef
13.
Cao L, Cai G, Xu F et al (2016) Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy. Medicine 95:e4230CrossRef
14.
Lanning RM, Morrow M, Riaz N et al (2015) The effect of adjuvant trastuzumab on locoregional recurrence of human epidermal growth factor receptor 2-positive breast cancer treated with mastectomy. Ann Surg Oncol 22:2517–2525CrossRef
15.
Kim MM, Dawood S, Allen P et al (2012) Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer 118:4936–4943CrossRef
16.
Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236–244CrossRef
17.
Yin W, Jiang Y, Shen Z, Shao Z, Lu J (2011) Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS ONE 6:e21030CrossRef
18.
Wallgren A, Bonetti M, Gelber RD et al (2003) Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21:1205–1213CrossRef
19.
Nahta R, O’Regan RM (2012) Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 135:39–48CrossRef
20.
Giuliano M, Trivedi MV, Schiff R (2013) Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care 8:256–262CrossRef
21.
Jwa E, Shin KH, Kim JY et al (2016) Locoregional recurrence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment. Cancer Res Treat 48:1363–1372CrossRef
22.
Danko ME, Bennett KM, Zhai J et al (2010) Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. J Am Coll Surg 210:797–805CrossRef
23.
Hatoum HA, Jamali FR, El-Saghir NS et al (2009) Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol 16:3388–3395CrossRef
24.
Bai LS, Chen C, Gong YP et al (2013) Lymph node ratio is more predictive than traditional lymph node stratification in lymph node positive invasive breast cancer. Asian Pac J Cancer Prev 14:753–757CrossRef
25.
Ahn SH, Kim HJ, Lee JW et al (2011) Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Res Treat 130:507–515CrossRef
26.
Kim J, Kim JH, Kim OB et al (2017) Clinical significance of the lymph node ratio in N1 breast cancer. Radiat Oncol J 35:227–232CrossRef
27.
Liu D, Chen Y, Deng M et al (2014) Lymph node ratio and breast cancer prognosis: a meta-analysis. Breast Cancer 21:1–9CrossRef
28.
Palmer AC, Sorger PK (2017) Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171:1678–1691CrossRef
29.
Horton JK, Halle J, Ferraro M et al (2010) Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys 76:998–1004CrossRef
Metadata
Title
Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy
Authors
Seung Hyuck Jeon
Kyung Hwan Shin
Jin Ho Kim
Kyubo Kim
In Ah Kim
Kyung-Hun Lee
Tae-Yong Kim
Seock-Ah Im
Publication date
01-12-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4966-9

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue

Epidemiology

Obesity and mortality after locoregional breast cancer diagnosis

Preclinical study

IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells

Clinical trial

Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer

Review

The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view

Preclinical study

Micro-computed tomography enables rapid surgical margin assessment during breast conserving surgery (BCS): correlation of whole BCS micro-CT readings to final histopathology

Preclinical study

Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits